QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Biosimilars and Generic Medicines—Regulatory and Pharmacovigilance Differences

Test your understanding of the concepts covered by Biosimilars and Generic Medicines: Regulatory and Pharmacovigilance Differences.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A cluster of adverse events appears to involve one biological product batch shortly after a manufacturing change. What is the most appropriate initial interpretation?

The manufacturing change is proven to have caused the events The events must be unrelated because biological products are expected to vary The temporal association warrants investigation integrating pharmacovigilance, quality, manufacturing and clinical evidence The cases should immediately be classified as a class-wide biological-product risk

Question 2 of 10 Which statement best explains why a biosimilar is not classified as a generic of a biological medicine?

Biological medicines are never eligible for abbreviated authorisation The active substance and product characteristics of biological medicines cannot ordinarily be demonstrated through the same exact-identity and conventional equivalence approach used for chemically defined substances Biosimilars must always undergo the complete clinical development programme of a new active substance Generic medicines are assessed only for safety, whereas biosimilars are assessed only for efficacy

Question 3 of 10 What is the most defensible interpretation of a new adverse-event pattern observed with a biosimilar but not previously highlighted for its reference product?

It automatically demonstrates that the biosimilar is intrinsically less safe It should be investigated as a potentially product-specific or broader concern using comparative, clinical, quality and reference-product evidence It must be dismissed because the reference product has an established safety profile It proves that all products with the same international non-proprietary name share the pattern

Question 4 of 10 What does the article identify as the strongest evidence that a pharmacovigilance system is functioning effectively for these products?

The ability to pool all cases under a common active-substance identifier The ability to reconstruct a significant safety issue from exposure and product identification through assessment, decision-making and follow-up The absence of any product-specific safety reports The use of identical assessment procedures for every generic and biosimilar

Question 5 of 10 Which statement best characterises the role of the reference medicine in biosimilar assessment?

It is used only to provide the invented name of the proposed product It provides prior biological and clinical knowledge and serves as the comparator in a structured similarity assessment It becomes the legally recorded exposure whenever a biosimilar adverse reaction is reported It is relevant only after authorisation and has no role in development

Question 6 of 10 Which statement best describes the relationship between pharmacovigilance and quality systems?

Pharmacovigilance should independently determine manufacturing causality without quality input Quality systems should resolve all clinical safety questions without pharmacovigilance assessment Safety reports and quality complaints should have controlled interfaces because either may contain information relevant to the other function Quality information is relevant only for biosimilars and never for generics

Question 7 of 10 Which statement best describes the common pharmacovigilance framework for generics and biosimilars?

Biosimilars operate under a completely separate pharmacovigilance system because their development is based on comparability Both are subject to the general EU pharmacovigilance framework, although the scientific context and product-specific considerations differ Generics are subject only to quality surveillance and not general GVP The applicable pharmacovigilance standards depend solely on whether substitution is permitted nationally

Question 8 of 10 What is the most appropriate distinction between EU scientific interchangeability and automatic substitution?

They are identical concepts controlled exclusively by EMA Scientific interchangeability is a conclusion about use of authorised biosimilars, whereas automatic substitution is a national policy decision Automatic substitution establishes biosimilarity, while scientific interchangeability concerns only pricing Neither concept has any relevance to exposure reconstruction

Question 9 of 10 Which statement about immunogenicity is most accurate?

Every antibody response is necessarily an adverse event Immunogenicity is irrelevant after biosimilar authorisation if comparability was established Clinically important immune responses may affect exposure, efficacy, activity or tolerability and should be interpreted in relation to outcomes Immunogenicity is a defining development issue for all small-molecule generics to the same extent as for therapeutic proteins

Question 10 of 10 Which scenario most clearly illustrates why the actual administered product must be retained in a safety case?

A biosimilar event is already listed for the reference product A suspected contamination or batch-related problem may affect only one authorised product The patient received treatment for an indication also authorised for the reference medicine The same active substance has been used in several countries

Knowledge Assessment: Biosimilars and Generic Medicines—Regulatory and Pharmacovigilance Differences

Cookie Settings